Bruker (NASDAQ:BRKR) Trading Up 7.7% – Here’s Why

Bruker Corporation (NASDAQ:BRKR)’s stock price traded up 7.7% during mid-day trading on Tuesday . The company traded as high as $60.63 and last traded at $60.4980. Approximately 396,004 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 2,379,252 shares. The stock had previously closed at $56.17.

Analyst Ratings Changes

Several research firms have issued reports on BRKR. Guggenheim raised their price target on shares of Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Citigroup raised their target price on shares of Bruker from $44.00 to $60.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Stifel Nicolaus set a $45.00 target price on shares of Bruker in a research note on Friday, May 8th. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating for the company. Finally, TD Cowen reiterated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has a consensus rating of “Hold” and a consensus price target of $56.79.

Bruker Trading Down 1.1%

The business’s 50-day moving average price is $55.61 and its 200 day moving average price is $46.12. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm has a market capitalization of $9.09 billion, a price-to-earnings ratio of -248.92, a PEG ratio of 1.93 and a beta of 1.29.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million during the quarter, compared to analyst estimates of $795.62 million. During the same period last year, the business earned $0.47 EPS. The business’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a dividend of $0.05 per share. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BRKR. Thrivent Financial for Lutherans raised its holdings in shares of Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the period. SG Americas Securities LLC lifted its position in shares of Bruker by 134.5% in the 4th quarter. SG Americas Securities LLC now owns 99,173 shares of the medical research company’s stock worth $4,672,000 after buying an additional 56,880 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Bruker by 202.7% in the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock valued at $1,946,000 after buying an additional 27,659 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Bruker by 317.7% in the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the period. Finally, VELA Investment Management LLC grew its position in shares of Bruker by 51.0% during the 4th quarter. VELA Investment Management LLC now owns 102,700 shares of the medical research company’s stock valued at $4,838,000 after buying an additional 34,700 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.